Spinal fluid can help diagnose Alzheimer’s
|
|
Measuring certain proteins in spinal fluid can accurately diagnose Alzheimer’s and predict which patients with memory problems will develop the fatal brain-wasting disease, Belgian researchers said on Monday.
And they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.
“The unexpected presence of the Alzheimer’s disease signature in more than one-third of cognitively normal subjects suggests that Alzheimer’s disease pathology is active and detectable earlier than has heretofore been envisioned,” Geert De Meyer of Ghent University in Belgium and colleagues wrote.
Eye disorder common among diabetic adults
|
|
Nearly 30 percent of U.S. diabetics over the age of 40 may have a diabetes-related eye disorder, with 4 percent of this population affected severely enough that their vision is threatened, suggests a new study.
The condition, known as diabetic retinopathy, involves damage to the eye’s retina and is the leading cause of new cases of legal blindness among U.S. adults between 20 and 74 years old. It also costs the U.S. approximately $500 million every year.
“The number of people with diabetes is increasing in this country,” lead researcher Dr. Xinzhi Zhang, of the Centers for Disease Control and Prevention in Atlanta, told Reuters Health.
Study Shows Physicians Reluctant to Use Chemoprevention for Prostate Cancer
|
|
Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
The first results of the PCPT were published in 2003 in The New England Journal of Medicine and were widely reported. The randomized controlled trial consisted of 18,000 men and showed a 25 percent reduced risk of prostate cancer.
Unfortunately, it also showed a 27 percent increased risk in high-grade tumors, which was noted in an accompanying editorial. Ian Thompson, M.D., chairman of the department of urology at the University of Texas Health Science Center, who led the study, said the editorial may have colored the perception of finasteride.
